A cross-sectional study sought to determine how caregiving responsibilities affect mental health of partner-caregivers.
Avelumab did not improve progression-free survival when given concurrently with chemotherapy or as maintenance.
Most adverse events in the olaparib arm were manageable with supportive treatment or dose modifications.
PARP inhibitor use increased regardless of BRCA mutation status.
There was no improvement in progression-free or overall survival.